Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient‐specific tumour idiotype protein or idiotype (VDJ)‐derived class I‐restricted peptides

Summary Fifteen multiple myeloma (MM) patients who had failed maintenance therapy after tandem autologous stem cell transplantation underwent anti‐idiotype (Id) vaccination with dendritic cells (DCs). CD14+‐derived DCs were loaded with the autologous Id as whole protein (=6) or Id‐derived class I‐re...

Ausführliche Beschreibung